Core Viewpoint - Mass spectrometry technology is a core tool for precise diagnosis, but its clinical adoption is hindered by the mismatch between research equipment and clinical settings [3][4]. Group 1: Product Development - YS Micro 480MD, a liquid chromatography-tandem mass spectrometry system developed by Yingsheng Bio, has been approved for market release, noted for its "small size, ease of operation, and low maintenance" features [3][4]. - The clinical mass spectrometry industry is experiencing a registration certificate explosion, with an increase in domestic companies investing in research and development [4]. Group 2: Market Trends - Mass spectrometry detection, with its high sensitivity advantages, has penetrated various clinical scenarios, including newborn genetic metabolic disease screening, and has the potential to become a standardized diagnostic platform in hospitals [4]. - Recent national policies have created a supportive framework for the development of clinical mass spectrometry, including incorporating it into development plans and mandating government procurement of domestic products, which has stimulated significant demand [4].